Trial Profile
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Drug-Drug Interaction Potential Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy®) in Healthy Adult Subjects
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Bemnifosbuvir/Ruzasvir (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications Hepatitis B; Hepatitis C; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Atea Pharmaceuticals
- 12 Apr 2024 New trial record